Stock Analysis
Omeros Corporation (OMER) Stock Analysis
Omeros Corporation (OMER) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Omeros Corporation (OMER) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
OMER at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $17.49 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $1.26B |
| P/E Ratio (TTM) | 9.16 |
| Forward P/E | — |
| EPS (Q2 FY2026) | $0.18 |
| Revenue (Q2 FY2026) | $28.53M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.6 |
| Volume | 737.38K |
| 52-week range | $6.24-$21.24 |
| RSI 14 | 47.88 |
| 50-Day SMA | $18.27 |
| 200-Day SMA | $13.77 |
| Analyst Price Target | $22.00 |
| Next Earnings | Nov 16, 2026 |
OMEROmeros Corporation
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum79
- Value73
- Quality55
- Risk resilience33
- Sentiment—
OMER Stock Analysis Summary
Omeros Corporation (OMER) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk resilience is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, OMER has AIQ Score of 64/100 with Momentum base of 79/100 and fading Risk resilience at 33/100. Wait for component alignment before adding exposure.
Momentum (79/100) leads while Risk resilience (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.78% stock move · OMER classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is OMER Bullish or Bearish Right Now?
OMER currently has a neutral overall setup. Momentum is the strongest factor at 79/100, while Risk Resilience is weakest at 33/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 79/100.
- - Analyst target implies +25.79% upside from the latest quote.
- - Risk Resilience is weak at 33/100.
- - Technical consensus has more sell votes than buy votes (27 vs 11).
Current Consensus
OMER's Technical Analysis Consensus is currently Sell, with 11 buy, 8 neutral, and 27 sell votes. OMER's 14-day RSI is 47.88, which places the stock in a neutral momentum range. OMER's beta is 1.6, indicating greater market sensitivity than the broad market.
What Changed in OMER?
The largest recent change in OMER is Momentum moving down by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the OMER Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
OMER Decision Framework
Public evidence layers, setup checks, and risk context for Omeros Corporation.
Omeros Corporation (OMER) Stock Analysis
Omeros Corporation has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 79/100. Beta is 1.6, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | OMER is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 79/100 while risk lags at 33/100. |
| Factor Evidence | Momentum 79/100 · Value 73/100 · Quality 55/100 · Risk 33/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 79/100.
Momentum is 79/100 and RSI (14) is 47.9.
OMER is in a Neutral regime at 64/100.
Risk factor is 33/100 with beta 1.6 and annual volatility 110.84%.
Current conflict: momentum leads at 79/100 while risk lags at 33/100.
OMER Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
OMER Fundamentals
OMER valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
OMER Technical Analysis
OMER technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
OMER Stock Catalysts
Track OMER earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
OMER Dividend Analysis
OMER dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
OMER Financial Data
OMER revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
OMER Risk Analysis
OMER volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
OMER Stock News
OMER stock news, market tone, recent headlines, and catalyst context.
OMER vs Biotechnology Peers
Current peer cohort: OMER · ONC · ORKA · PCVX · PGEN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| OMER Current stock | 64/100 | 73/100 | 79/100 | 33/100 | 1.36 | 110.84% | Current |
| ONC BeOne Medicines AG | 80/100 | 71/100 | 91/100 | 72/100 | 0.42 | 34.16% | OMER vs ONC |
| ORKA Oruka Therapeutics, Inc. | 77/100 | — | 81/100 | 53/100 | 2.29 | 69.09% | OMER vs ORKA |
| PCVX Vaxcyte, Inc. | 66/100 | — | 81/100 | 53/100 | 0.79 | 56.19% | OMER vs PCVX |
| PGEN Precigen, Inc. | 55/100 | 63/100 | 55/100 | 31/100 | 0.57 | 85.43% | OMER vs PGEN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for OMER: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching OMER
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for OMER
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
OMER Stock FAQ
What is OMER stock price today?
Omeros Corporation's current stock price is $17.49. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is OMER bullish or bearish right now?
OMER's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is OMER's market cap?
OMER's market cap is $1.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is OMER's current P/E ratio?
OMER's current P/E ratio is 9.16 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is OMER's RSI?
OMER's 14-day RSI is 47.88 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is OMER above its 50-day and 200-day moving averages?
OMER is -4.25% from its 50-day SMA and 27.04% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is OMER's next earnings date?
OMER's next earnings date is currently listed as Nov 16, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does OMER pay a dividend?
OMER's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.